13/19
3.4 / 5 stars
All 19 Win/Lose results and 101 gray no-data contests shown below
NPCE Roast Me summary
NeuroPace Inc (NPCE). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return No data; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return No data; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return No data; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return No data; Revenue growth Win; EPS growth No data.
Trailing 1 year (4 quarters): 4 wins, 0 losses, 8 no dataLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/1 |
No dataNPCE / S&P / 15.20% |
WinNPCE / S&P 16.90% / 15.00% |
No dataNPCE / S&P / 50.40% |
| 2026-Q11/1 |
No dataNPCE / S&P / -4.33% |
WinNPCE / S&P 13.29% / 11.30% |
No dataNPCE / S&P / 27.70% |
| 2025-Q41/1 |
No dataNPCE / S&P / 2.65% |
WinNPCE / S&P 25.13% / 9.00% |
No dataNPCE / S&P / 13.40% |
| 2025-Q31/1 |
No dataNPCE / S&P / 8.12% |
WinNPCE / S&P 18.83% / 4.61% |
No dataNPCE / S&P / 13.45% |
| 2025-Q21/1 |
No dataNPCE / S&P / 10.94% |
WinNPCE / S&P 17.73% / 4.83% |
No dataNPCE / S&P / 10.63% |
| 2025-Q11/1 |
No dataNPCE / S&P / -4.27% |
WinNPCE / S&P 22.05% / 4.98% |
No dataNPCE / S&P / 10.57% |
| 2024-Q41/1 |
No dataNPCE / S&P / 2.41% |
WinNPCE / S&P 22.14% / 5.25% |
No dataNPCE / S&P / 6.15% |
| 2024-Q31/1 |
No dataNPCE / S&P / 5.89% |
WinNPCE / S&P 27.00% / 5.89% |
No dataNPCE / S&P / 6.11% |
| 2024-Q21/1 |
No dataNPCE / S&P / 4.28% |
WinNPCE / S&P 30.75% / 5.38% |
No dataNPCE / S&P / 5.12% |
| 2024-Q11/1 |
No dataNPCE / S&P / 10.56% |
WinNPCE / S&P 42.07% / 5.71% |
No dataNPCE / S&P / 5.59% |
| 2023-Q41/1 |
No dataNPCE / S&P / 11.69% |
WinNPCE / S&P 43.72% / 6.81% |
No dataNPCE / S&P / 7.78% |
| 2023-Q31/1 |
No dataNPCE / S&P / -3.27% |
WinNPCE / S&P 37.66% / 7.52% |
No dataNPCE / S&P / -5.03% |
| 2023-Q21/1 |
No dataNPCE / S&P / 8.74% |
WinNPCE / S&P 28.01% / 9.50% |
No dataNPCE / S&P / -8.57% |
| 2023-Q10/1 |
No dataNPCE / S&P / 7.50% |
LoseNPCE / S&P 7.23% / 10.77% |
No dataNPCE / S&P / -15.69% |
| 2022-Q40/1 |
No dataNPCE / S&P / 7.56% |
LoseNPCE / S&P 0.75% / 11.88% |
No dataNPCE / S&P / -17.99% |
| 2022-Q30/1 |
No dataNPCE / S&P / -4.88% |
LoseNPCE / S&P -2.69% / 13.47% |
No dataNPCE / S&P / -1.41% |
| 2022-Q20/1 |
No dataNPCE / S&P / -16.10% |
LoseNPCE / S&P -9.42% / 13.71% |
No dataNPCE / S&P / 11.04% |
| 2022-Q10/1 |
No dataNPCE / S&P / -4.60% |
LoseNPCE / S&P 6.98% / 15.97% |
No dataNPCE / S&P / 42.23% |
| 2021-Q40/1 |
No dataNPCE / S&P / 11.03% |
LoseNPCE / S&P 9.83% / 15.00% |
No dataNPCE / S&P / 96.40% |
| 2021-Q30/0 |
No dataNPCE / S&P / 0.58% |
No dataNPCE / S&P / 10.77% |
No dataNPCE / S&P / 69.42% |
| 2021-Q20/0 |
No dataNPCE / S&P / 8.55% |
No dataNPCE / S&P / 6.58% |
No dataNPCE / S&P / 51.81% |
| 2021-Q10/0 |
No dataNPCE / S&P / 6.17% |
No dataNPCE / S&P / -1.06% |
No dataNPCE / S&P / 7.39% |
| 2020-Q40/0 |
No dataNPCE / S&P / 12.15% |
No dataNPCE / S&P / -3.72% |
No dataNPCE / S&P / -33.42% |
| 2020-Q30/0 |
No dataNPCE / S&P / 8.93% |
No dataNPCE / S&P / -2.04% |
No dataNPCE / S&P / -27.10% |
| 2020-Q20/0 |
No dataNPCE / S&P / 20.54% |
No dataNPCE / S&P / -0.46% |
No dataNPCE / S&P / -27.11% |
| 2020-Q10/0 |
No dataNPCE / S&P / -19.60% |
No dataNPCE / S&P / 3.47% |
No dataNPCE / S&P / -14.75% |
| 2019-Q40/0 |
No dataNPCE / S&P / 9.07% |
No dataNPCE / S&P / 5.36% |
No dataNPCE / S&P / 2.99% |
| 2019-Q30/0 |
No dataNPCE / S&P / 1.70% |
No dataNPCE / S&P / 5.02% |
No dataNPCE / S&P / 0.21% |
| 2019-Q20/0 |
No dataNPCE / S&P / 4.30% |
No dataNPCE / S&P / 6.64% |
No dataNPCE / S&P / 8.65% |
| 2019-Q10/0 |
No dataNPCE / S&P / 13.65% |
No dataNPCE / S&P / 8.12% |
No dataNPCE / S&P / 14.29% |
| 2018-Q40/0 |
No dataNPCE / S&P / -13.52% |
No dataNPCE / S&P / 9.05% |
No dataNPCE / S&P / 18.23% |
| 2018-Q30/0 |
No dataNPCE / S&P / 7.71% |
No dataNPCE / S&P / 10.21% |
No dataNPCE / S&P / 19.06% |
| 2018-Q20/0 |
No dataNPCE / S&P / 3.43% |
No dataNPCE / S&P / 9.03% |
No dataNPCE / S&P / 14.46% |
| 2018-Q10/0 |
No dataNPCE / S&P / -0.76% |
No dataNPCE / S&P / 7.68% |
No dataNPCE / S&P / 12.46% |
| 2017-Q40/0 |
No dataNPCE / S&P / 6.64% |
No dataNPCE / S&P / 7.03% |
No dataNPCE / S&P / 13.82% |
| 2017-Q30/0 |
No dataNPCE / S&P / 4.48% |
No dataNPCE / S&P / 5.68% |
No dataNPCE / S&P / 17.57% |
| 2017-Q20/0 |
No dataNPCE / S&P / 3.09% |
No dataNPCE / S&P / 4.83% |
No dataNPCE / S&P / 17.74% |
| 2017-Q10/0 |
No dataNPCE / S&P / 6.07% |
No dataNPCE / S&P / 3.67% |
No dataNPCE / S&P / 13.32% |
| 2016-Q40/0 |
No dataNPCE / S&P / 3.82% |
No dataNPCE / S&P / 2.09% |
No dataNPCE / S&P / 7.05% |
| 2016-Q30/0 |
No dataNPCE / S&P / 3.85% |
No dataNPCE / S&P / 0.20% |
No dataNPCE / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |